What do people live for? A few takeaways from the 2019 Georgia Bio Innovation Summit

Georgia’s life sciences community contributes more than $20 billion to the state’s GDP according to a recent report from RTI for Georgia Bio, the state’s life sciences partnership. Employment in the sector grew by nearly 15% from 2007 to 2017, almost double the national average. 

The 2019 edition of the Georgia Bio Innovation Summit convened hundreds of life science executives, scientists, researchers and public policy officials earlier this month. With four industry tracks the program had something for everyone no matter their particular place in Georgia’s science ecosystem.

Remembering the collective “why”

Marc Boutin, CEO of the National Health Council, inspired everyone in attendance during his lunch keynote address. “Your innovations help people live their dreams,” he said. “Those dreams are not always about survival.”

“What do people live for?” What a powerful question. Marc shared the following video ad from TC Bank.

Will healthcare ever realize “value?”

During the fireside chat portion of the lunch session, Sheila Burke, strategic advisor and chair for the government relations and public policy group of Baker Donelson underscored one of the greatest challenges in shifts from fee-for-service to value-based care. Quality and value are highly nuanced and highly personal. Yet patient input where value is currently assigned is limited.

If we define value as outcomes divided by cost, the shift from fee-for-service to value-based care may be impossible or mostly ineffective until this country assigns some dollar amount to quality adjusted life years, particularly when patient interests may not always be about longevity. Much like surgery for men with prostate cancer over 70, therapies and procedures that cost seven figures or more are simply not a value-based proposition for an 80 year old when allocating scarce resources. However, they may well present value for those of a much younger age.

As always, the opportunity to connect with colleagues and expand professional networks was of high value. There were well over 500 registrants and the ballroom was near standing room only for the lunch program. Here are a few other session insights.

The latest boobytrap waiting to maim medtech and life science innovators

Design history file remediation remains a sizeable stumbling block for innovators seeking investment to advance their products is. It can – and does – kill deals. But GCMI CEO Tiffany Wilson brought an emerging issue of equal risk to light. It’s the supply chain. Will the materials for your custom circuitry still be readily available (and at a cost that does not ruin your price structure) in five years? 

Who will get your products to markets around the globe? How sensitive are they to time, temperature and other rigors of transport? Georgia’s logistics capabilities make Atlanta an excellent home for medical product companies and innovators. Beyond carriers like UPS, are there better ways to get them there? Dr. Marc Prausnitz at Georgia Tech is developing microneedle technology that presents a better way to get critical medications and vaccines to patients around the globe. 

Advice for medical product startups and innovators from the investors

Founders, your team will be talking to the money (VCs, investors, potential acquirers, etc.) and many times you won’t be in the room. This underscores the importance of culture and team building, which is typically not a great strength among founders of medtech and life science companies. Entrepreneurs seeking seed stage funding, up to $2 million or thereabout, your people are your greatest asset, not your technology or IP according to Kim Seals, general partner with The JumpFund.

Protip: if you say your innovation has no competition, you don’t know your market. And if you tell an investor theirs is the ‘last money in,’ you do not have a realistic view of the actual time and cost requirements of commercializing medical products. Thanks to Tom Callaway, venture partner with HealthQuest Capital for driving those points home.

We thank Georgia Bio, the board, staff and program steering committee for arranging and hosting an outstanding event. We are already looking forward to 2020 while putting what we learned to use and advancing conversations with colleagues new and old we saw this year.

Follow Georgia Bio on LinkedIn , Twitter and Facebook

December 22, 2025
Dear Georgia Life Sciences Community, As we reflect on the past year, I want to extend my sincere thanks to our Georgia Life Sciences members for making it such an impactful one. Your engagement and leadership continue to move our industry forward and advance our shared strategic priorities— driving strong policy, expanding the talent pipeline, and creating intentional spaces for collaboration across Georgia’s life sciences ecosystem. Our Year in Review captures the progress we’ve made together across these priorities and highlights the collective impact our members are having statewide—from strengthening the workforce and supporting manufacturing growth to elevating Georgia’s position as a national life sciences leader. This progress is only possible because of the collaboration, commitment, and insight of our member community. 
By Maria Thacker Goethe December 20, 2025
The biopharmaceutical industry is growing America’s manufacturing and R&D capabilities to develop the next generation of treatments. A recent study from PILMA quantified the impact of the industry’s investment in American infrastructure on the economy and union workforce across 18 states from 2019-2024. The study found that across the 18 states included, the biopharmaceutical industry: Supported the American economy by investing $86.5B in R&D and manufacturing infrastructure and developing 1000+ construction projects at over 700 distinct facilities. Strengthened the American workforce by generating $2.6B in skilled union wages and providing $19M in support for union apprenticeships. The impact of the biopharmaceutical industry’s investment in American manufacturing and union jobs extends beyond direct benefits, spurring additional economic activity in the communities where workers live. This is known as the multiplier effect . On average, every $1 of new investment in a U.S. biopharmaceutical manufacturing facilities generates an additional $1.59 in further economic activity (2.59x times the initial investment value). The industry’s $86.5B investment in R&D and manufacturing infrastructure has a total economic impact of $224B. Check out this resource to learn more about how biopharmaceutical investment in American infrastructure supports America’s workers and communities. For more on how biopharmaceutical companies are investing in America’s future, visit innovation.org/america-investment .
December 10, 2025
Georgia Life Sciences has joined 43 state and regional life sciences organizations in signing a national Council of State Bioscience Associations (CSBA) letter calling on Congress to take immediate action on three bipartisan policy priorities that are essential to sustaining U.S. leadership in biomedical innovation and supporting patients nationwide. With Congress back in session and several critical programs at risk of expiring, the letter urges congressional leaders to advance the following provisions without delay: 1. Reauthorize the Rare Pediatric Disease Priority Review Voucher (PPRV) Program The PPRV program has been instrumental in incentivizing the development of therapies for children with rare and life-threatening conditions. Its lapse threatens to slow or halt research that families across the country are counting on. 2. Extend the SBIR/STTR Programs The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs provide crucial early-stage capital for emerging biotech and medtech companies—many of them in Georgia. Without reauthorization, hundreds of innovative small businesses face uncertainty, jeopardizing new therapies, diagnostics, and technologies in the pipeline, 3. Advance PBM Transparency Reforms Greater transparency and accountability within pharmacy benefit manager (PBM) practices are needed to ensure that savings reach patients and employers. Reforming PBM operations is essential to strengthening access and affordability across the healthcare system. A Unified Message from the Life Sciences Community The sign-on letter reflects broad, bipartisan alignment across the national life sciences ecosystem: researchers, entrepreneurs, investors, patient advocates, and state associations all share a common message— these programs underpin America’s global competitiveness and are vital to patients who rely on continued scientific progress. Georgia Life Sciences has shared the letter with members of Georgia’s congressional delegation and will continue engaging with policymakers to emphasize the importance of swift action.
MORE POSTS